Evidence map›Paper›PMID 34067117›Full record

ArticleCancers2021

IGF2 Mediates Resistance to Isoform-Selective-Inhibitors of the PI3K in HPV Positive Head and Neck Cancer.

Mai Badarni, Manu Prasad, Artemiy Golden, Baisali Bhattacharya, Liron Levin, Ksenia M Yegodayev, Orr Dimitstein, Ben-Zion Joshua, Limor Cohen, Ekaterina Khrameeva and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 4 countries.

Mai BadarniThe Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Science, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.
Manu PrasadThe Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Science, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.ORCID 0000-0001-7690-3511
Artemiy GoldenCenter of Life Sciences, Skolkovo Institute of Science and Technology, 121205 Moscow, Russia.
Baisali BhattacharyaThe Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Science, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.
Liron LevinBioinformatics Core Facility, National Institute for Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.
Ksenia M YegodayevThe Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Science, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.
Orr DimitsteinFaculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.
Ben-Zion JoshuaFaculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.
Limor CohenThe Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Science, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.
Ekaterina KhrameevaCenter of Life Sciences, Skolkovo Institute of Science and Technology, 121205 Moscow, Russia.
Dexin KongSchool of Pharmaceutical Sciences, Tianjin Medical University, Tianjin 300070, China.ORCID 0000-0002-8064-1435
Angel PorgadorThe Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Science, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.
Alex BraimanThe Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Science, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.
Jennifer R GrandisDepartment of Otolaryngology-Head and Neck Surgery, University of California San Francisco, San Francisco, CA 94143, USA.
Barak RotblatThe National Institute for Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer Sheva 84105, Israel.ORCID 0000-0003-2985-7115
Moshe ElkabetsThe Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Science, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.ORCID 0000-0003-3634-9098
Ben-Gurion University of the Negev · ILSkolkovo Institute of Science and Technology · RUTianjin Medical University · CNUniversity of California, San Francisco · US

Funding

Integrating genomics and the protein interactome for HPV+ head and neck cancer therapyR35CA231998 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2018 to 2024
$6.2M
PI3K Pathway Mutations in Head and Neck CancerR01DE023685 · NIDCR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GRANDIS, JENNIFER RUBIN, JOHNSON, DANIEL E · 2014 to 2023
$5.1M
NCI NIH HHS R35 CA231998NIDCR NIH HHS R01 DE023685
6 · The paper itself

Abstract

Over 50% of human papilloma positive head-and-neck cancer (HNC

Indexed as

drug combinationshead and neck cancerHPVIGF1RIGF2PI3Ktherapy resistance

Identifiers

PMID34067117
PMCPMC8125641
OpenAlexW3162141400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.